Carnipin

Carnipin

nicardipine

Manufacturer:

Ildong Pharm

Distributor:

Bellus Life Solutions
Concise Prescribing Info
Contents
Nicardipine HCl
Indications/Uses
Acute life-threatening HTN, particularly in the event of: Malignant arterial HTN/hypertensive encephalopathy; aortic dissection, when short acting β-blocker therapy is not suitable or in combination w/ a β-blocker when β-blockade alone is note effective; severe pre-eclampsia; post-op HTN.
Dosage/Direction for Use
Adult Continuous admin at a rate of 3-5 mg/hr for 15 min, increased by increments of 0.5 or 1 mg every 15 min. Max: 15 mg/hr. Maintenance: When target pressure is reached, dose should be reduced progressively, usually between 2 & 4 mg/hr. Childn Initially 0.5-5 mcg/kg/min. Maintenance: 1-4 mcg/kg min. Pregnant & elderly Initially 1-5 mg/hr. After 30 min, rate should be increased or decreased by increments of 0.5 mg/hr. Max: 15 mg/hr.
Contraindications
Hypersensitivity. Severe aortic stenosis, compensatory HTN (ie, in case of arteriovenous shunt or aortic coarctation), unstable angina, w/in 8 days after MI. Fructose intolerance.
Special Precautions
May produce systemic hypotension & reflex tachycardia. Patients w/ CHF or pulmonary edema in patients receiving concomitant β-blockers; suspected coronary ischemia; acute cerebral infarction. Worsen portal vein HTN & portal-systemic collateral blood flow in index in cirrhotic patients. History of hepatic dysfunction or w/ impaired hepatic function. Risk of severe maternal hypotension & fetal hypoxia during pregnancy. Not to be used during lactation. Low birth wt infant, newborn, nursing infant, infant & childn (w/ renal impairment).
Adverse Reactions
Headache, dizziness, peripheral edema, palpitations & flushing.
Drug Interactions
May enhance -ve inotropic effect of β-blockers. Fatal ventricular fibrillation w/ dantrolene. Risk of pulmonary edema or excessive decrease in BP w/ Mg sulfate. Decreased plasma conc w/ CYP3A4 inducers (eg, carbamazepine, phenobarb, phenytoin, fosphenytoin, primidone & rifampicin). Increased plasma conc w/ CYP3A4 inhibitors (eg, cimetidine, itraconazole & grapefruit juice). Increased risk of adverse events w/ itraconazole. Elevated plasma levels of cyclosporine, tacrolimus & sirolimus. Increased plasma levels of digoxin. Potentiate antihypertensive effect w/ baclofen, α-blockers, TCAs, neuroleptics, opioids & amifostine. Decreased antihypertensive effect w/ IV corticosteroids & tetracosactide (except for hydrocortisone used as replacement therapy in Addison's disease). Induced potential additive or synergistic hypotensive effect w/ inhalational anesth.
MIMS Class
ATC Classification
C08CA04 - nicardipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Carnipin soln for IV infusion 1 mg/mL
Packing/Price
10 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in